Abstract: The present disclosure is directed to pharmaceutical formulations comprising an amorphous inhibitor of hepatitis C virus NS5A. These pharmaceutical formulations may be prepared by roller-compaction or wet-granulation methods. The present disclosure is also directed to oral dosage forms, such as tablets, comprising such pharmaceutical formulations.
Type:
Application
Filed:
September 23, 2024
Publication date:
January 9, 2025
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Sutthilug Sotthivirat, Joyce Stellabott, Walter R. Wasylaschuk
Abstract: A liquid-crystal (LC) medium which is based on a mixture of polar compounds and is substantially dielectrically neutral, its use for optical, electro-optical and electronic purposes, in particular as optical retarder or optical compensator in LC displays, an optical retarder or optical compensator containing the LC medium, an optical, electrooptical or electronic device containing the optical retarder or optical compensator, and a process of manufacturing the optical retarder or optical compensator.
Type:
Grant
Filed:
May 23, 2023
Date of Patent:
January 7, 2025
Assignee:
Merck Patent GmbH
Inventors:
Sven Christian Laut, Tzu-Huan Tseng, Kuang-Ting Chou, Chi-Shun Huang
Abstract: Provided herein are electrospun or electroblown non-woven fiber membranes, methods of making such membranes and lateral flow diagnostic devices comprising such membranes.
Type:
Grant
Filed:
July 20, 2018
Date of Patent:
January 7, 2025
Assignees:
Merck Millipore Ltd., The Provost Fellows Foundation Scholars and the Other Members of Board of the College of the Holy Cross
Inventors:
William Cataldo, Inga Elkina, Kamran Beyzavi, Thomas Fitzgerald, Dennis Aquino, Daniel Callahan, Michael Mansfield, Mikhail Kozlov, Gabriel Tkacik, Murugan Rajendiran, Ramesh Babu Padamati
Abstract: A polymerisable LC material comprising one or more di- or multireactive mesogenic compounds and one or more compounds of formula UVI, and one or more compounds of formula UVII, Further, a method for its preparation, a polymer film with improved thermal durability and UV stability obtainable from a corresponding polymerisable LC material, a method of preparation of such polymer film, and the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
Type:
Grant
Filed:
November 18, 2021
Date of Patent:
January 7, 2025
Assignee:
Merck Patent GmbH
Inventors:
Jin-Soon Park, Hoo-Yong Lee, Hyun-Jin Yoon, Heui-Seok Jin
Abstract: The present invention describes nitrogen-containing heterocycles substituted by carbazole groups, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.
Type:
Grant
Filed:
December 4, 2017
Date of Patent:
January 7, 2025
Assignee:
MERCK PATENT GMBH
Inventors:
Amir Parham, Jonas Kroeber, Dominik Joosten, Aurélie Ludemann, Tobias Grossmann, Philipp Stoessel, Christian Eickhoff
Abstract: The present invention relates to a compounds of formula I R1-(A1-Z1)r—B1—ZL-A2-(Z3-A3)s-G??(I) in which the occurring groups and parameters have the meanings given in claim 1, to the use thereof for the formation of molecular layers, in particular self assembled monolayers, to a process for the fabrication of a switching element for memristive devices comprising said molecular layers and to a memristic device comprising said switching element.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
January 7, 2025
Assignee:
MERCK PATENT GMBH
Inventors:
Peer Kirsch, Sebastian Resch, Henning Seim
Abstract: The present disclosure relates to methods of treating a cellular proliferative disorder (e.g., cancer) comprising administering: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I): wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
Abstract: This invention relates to a new stationary phase carrying boron clusters. Target molecules can interact with this stationary phase depending on the cluster type and the substituents. The stationary phase is suitable for SPE and chromatographic separations.
Type:
Application
Filed:
November 7, 2022
Publication date:
January 2, 2025
Applicant:
MERCK PATENT GMBH
Inventors:
Romas SKUDAS, Annika HOLZGREVE, Michael SCHULTE, Fabian KEPPNER, Tanja KNUPLEZ, Michael HAILMANN, Maik FINZE, Nikolai IGNATYEV
Abstract: The present disclosure relates to methods of treating a cellular proliferative disorder (e.g., cancer) comprising administering: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I): wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
Abstract: An ampoule includes a body having a cavity for storing a medicament, a neck coupled to the body and defining a nozzle in communication with the cavity of the body, a removable cap coupled to the nozzle, and an anti-choking miter coupled to the removable cap, the anti-chocking miter being wider than the removable cap.
Type:
Application
Filed:
November 11, 2022
Publication date:
January 2, 2025
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Ramprasad B. Halthore, Atul Karande, Derrick M. Smith
Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of a7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease. Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
Type:
Application
Filed:
September 19, 2022
Publication date:
January 2, 2025
Applicant:
MERCK SHARP & DOHME LLC
Inventors:
Ian M. Bell, Brendan M. Crowley, James Fells, Patrick Bazzini, Jean-Marie Contreras, Fabrice Garrido, Belinda C. Huff, Christophe Joseph, Christophe Morice, Dharam Paul, Aurelie Witzel
Abstract: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
Type:
Grant
Filed:
October 31, 2022
Date of Patent:
December 31, 2024
Assignee:
MERCK SHARP & DOHME LLC
Inventors:
Hubert Josien, Abbas Walji, Harold B. Wood, Fa-Xiang Ding, Jian Liu, Thomas Joseph Tucker, Michael Man-Chu Lo, Liangqin Guo
Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.
Type:
Grant
Filed:
April 29, 2024
Date of Patent:
December 31, 2024
Assignee:
MERCK SHARP & DOHME LLC
Inventors:
Feng Xu, Zhuqing Liu, Richard Desmond, Jeonghan Park, Alexei Kalinin, Birgit Kosjek, Hallena Strotman, Hongmei Li, Johannah Moncecchi
Abstract: A method of forming a conformal layer including TiN in a via includes introducing a precursor into a reaction chamber according to a first exposure schedule. The precursor includes non-halogenated metal-organic titanium. The first exposure schedule indicates precursor exposure periods. Each precursor exposure period is associated with a particular duration of time and a particular duty cycle over which to introduce the precursor during the particular duration of time. The method includes introducing a co-reactant into the reaction chamber according to a second exposure schedule. The co-reactant includes nitrogen. The second exposure schedule indicates co-reactant exposure periods. Each co-reactant exposure period is associated with a particular duration of time and a particular duty cycle over which to introduce the co-reactant during the particular duration of time. The method includes providing the conformal layer including TiN in the via based on said introducing the precursor and the co-reactant.
Type:
Grant
Filed:
December 6, 2022
Date of Patent:
December 31, 2024
Assignees:
The Regents of the University of California, Merck Patent GmbH
Inventors:
Andrew Kummel, Cheng-Hsuan Kuo, SeongUk Yun, Ravindra Kanjolia, Mansour Moinpour, Daniel Moser
Abstract: Described herein are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
Type:
Grant
Filed:
October 25, 2022
Date of Patent:
December 31, 2024
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Abdelghani Abe Achab, Zachary G. Brill, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Jing Su, Brandon A. Vara, Erin F. DiMauro
Abstract: An insulin conjugate comprising or consisting of a tetra-valent sugar cluster is described. The tetra-valent sugar cluster is provided by tetra-dentate linker having four arms, wherein each arm of the tetra-dentate linker is independently covalently linked to a ligand comprising or consisting of a saccharide, such as a monosaccharide, disaccharide, trisaccharide, tetrasaccharide, or branched trisaccharide. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose.
Type:
Application
Filed:
November 16, 2022
Publication date:
December 26, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Pei Huo, Songnian Lin, Christopher R. Moyes, Dmitri A. Pissarnitski, Zhiqiang Zhao, David N. Hunter, Yuping Zhu
Abstract: The invention provides compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0% oxidation of Met105 in the CDRH3 heavy chain region, and methods of obtaining the purified compositions. The invention also provides compositions comprising anti-PD-1 antibody main species and acidic species thereof, wherein the amount of acidic species is about 1.0-12.0%.
Type:
Application
Filed:
September 6, 2024
Publication date:
December 26, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Mark A. Brower, Chung-Jr Huang, Brian Wai Kwan, William Nicholas Napoli, Bhumit A. Patel, Nuno J. Dos Santos Pinto, Douglas Dennis Richardson, II, Sen Xu
Abstract: In some examples, a vial-to-syringe converter includes a plunger rod, an adapter including a body having a piercing spike, a receiver and a lumen extending between the spike and the receiver, the body further including at least one laterally-extending flange, and a needle in communication with the receiver and configured to deliver a medicament to a patient's body.
Type:
Application
Filed:
November 1, 2022
Publication date:
December 26, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Daniel A. Bonanno, Eduardo Cristofolli, Cassie Megna, Wail A. Rasheed, Ophelia L. Wells
Abstract: Described herein are compounds of Formula I; and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, m, n, and p are as defined herein. The compounds of Formula I, and pharmaceutically acceptable salts thereof, act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
Type:
Application
Filed:
October 24, 2022
Publication date:
December 26, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Abdelghani Abe Achab, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Brandon A. Vara, Hongjun Zhang
Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
Type:
Grant
Filed:
August 5, 2019
Date of Patent:
December 24, 2024
Assignees:
Merck Sharp & Dohme LLC, MSD International GmbH
Inventors:
Michelle Machacek, David Witter, Craig Gibeau, Chunhui Huang, Shuhei Kawamura, David L. Sloman, Phieng Siliphaivanh, Ryan Quiroz, Murray Wan, Sebastian Schneider, Charles S. Yeung, Michael H. Reutershan, Timothy J. Henderson, Jean-Laurent Paparin, Houcine Rahali, Jonathan M. E. Hughes, Sulagna Sanyal, Yingchun Ye, David A. Candito, Patrick S. Fier, Steven M. Silverman